The trial will involve ten patients, whose own immune system will be used to target this deadly brain tumour. The trial will use a new vaccine targeting Cytomegalovirus (CMV) for Glioblastoma, which has been developed in the United States. This is an exciting opportunity to help translate this discovery from the lab into an effective treatment for patients.
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are non-specific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. There is no clear way to prevent the disease. Typically, treatment involves surgery, after which chemotherapy and radiation therapy are used.
Dr John Howard Sampson, M.D., Ph.D, M.B.A, M.H.S.c, is the chief of the department of neurosurgery at Duke University where he serves as a professor of surgery, biomedical engineering, immunology, and pathology said "There have been surprisingly promising clinical outcomes in small studies of this investigational vaccine, which certainly support these advanced trials. Immunotherapy is giving real hope to those with glioblastoma."